Home › Companies › QNRX

Quoin Pharmaceuticals

QNRX Rare disease Lead: Phase 2 ★ Read the deep dive → 1 Biotech Distilled article ↓

Dermatology Immunology Small Molecule

Most recent annual filing: 2026-03-26

Pipeline (8 active programs)

QRX003

Small Molecule Target: kallikreins, serine protease

Netherton Syndrome Phase 2 topical Skinvisible
Peeling Skin Syndrome Phase 2 topical Skinvisible

QRX008

Small Molecule Target: VLA-4

Scleroderma Preclinical Queensland University of Technology

rapamycin

sirolimus · QRX009

Small Molecule Target: mTOR

Microcystic Lymphatic Malformations Preclinical topical University College Cork
Venous Malformations Preclinical topical University College Cork
Gorlin Syndrome Preclinical topical University College Cork
Epidermolysis Bullosa Preclinical topical University College Cork
Pachyonychia Congenita Preclinical topical University College Cork

Discontinued (1)

QRX007 — Netherton Syndrome · discontinued in July 2025 in light of expected near-term completion of QRX003 clinical program for NS

Biotech Distilled coverage (1)

2026-06-25 Quoin Pharmaceuticals (QNRX) — Scientific Deep Dive for QRX003 (QYLEKI) and Pipeline Products

Articles open on Substack. Some deep dives are subscriber-only.